Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07484724RecruitingPhase 2
JS212 combination therapy for advanced esophageal cancer
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06640725RecruitingPhase 2
TPEx chemo with maintenance immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy drugs (TPEx) followed by two immunotherapy drugs (avelumab and cetuximab) as a first treatment for head and neck cancer that has spread or come back. It is for people whose tumors show a protein called PD-L1 and who have not had chemotherapy for advanced disease before.
Vandœuvre-lès-NancyAges 18–74 - NCT06418061RecruitingPhase 1
Testing IBI3005 for advanced solid tumors
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
Jinan, ShandongAges 18 years+ - NCT06601075Recruiting
FDG and FAPI PET Scans for Advanced Colorectal Cancer
This trial uses two types of PET/CT scans (FDG and FAPI) to better see and track colorectal cancer that has spread to the belly lining (peritoneum). It aims to help doctors choose the best treatment by improving how they detect and monitor the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07469774RecruitingPhase 1/Phase 2
BC3195 plus Keytruda for advanced solid tumors
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07468851RecruitingPhase 1/Phase 2
Study of HS-10566 for high-risk bladder cancer that hasn't spread into muscle
This study tests a new treatment called HS-10566 for people with a type of bladder cancer that has not reached the muscle layer and is considered high-risk, where the usual treatments have not worked or were not an option. It aims to control the cancer and avoid the need for removing the bladder.
BeijingAges 18 years+ - NCT07454720RecruitingPhase 2/Phase 3
Study of Adebrelimab with SHR-8068 and chemoradiation before surgery for rectal cancer
This trial tests whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to standard chemoradiation before surgery can improve outcomes for adults with locally advanced rectal cancer that can be surgically removed.
Wuhan, HubeiAges 18–75 - NCT05841420RecruitingPhase 2
Lower-intensity chemo for fragile pancreatic cancer patients
This Phase 2 trial compares a standard gemcitabine approach versus a reduced-dose combination chemotherapy for people with pancreatic cancer that can’t be removed by surgery. It aims to find a treatment that works while being safer for “fragile” patients who can’t tolerate full-dose chemotherapy.
AalborgAges 18 years+ - NCT07449754RecruitingPhase 2
Belvarafenib with cobimetinib for NRAS-mutant melanoma
This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT07438106RecruitingPhase 2
HRS-4642 with chemo to shrink pancreatic cancer before surgery
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
NanjingAges 18–75 - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+ - NCT06470217RecruitingPhase 2
Study of tirilizumab plus chemo for advanced oral cancer
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75 - NCT06293651RecruitingPhase 1/Phase 2
Study of DA-4505 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called DA-4505, given alone or with another drug (pembrolizumab), for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against the cancer.
SeoulAges 18 years+ - NCT07407504RecruitingPhase 1
Targeted therapy for cancers with a specific gene change
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07407231Recruiting
Chemo and radiation for advanced inoperable pancreatic cancer
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
LjubljanaAges 18 years+ - NCT07406789RecruitingPhase 2
Personalized diet study for women with advanced breast or gynecologic cancer
This study tests whether a personalized dietary plan can help manage side effects and improve well-being in women with advanced breast or gynecologic cancer who are receiving antibody-drug conjugate (ADC) therapy. ADCs are a type of targeted cancer treatment that delivers chemotherapy directly to cancer cells.
Madrid, MadridAges 18 years+ - NCT07393542RecruitingPhase 3
Combination treatment for advanced bladder cancer
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07391618RecruitingPhase 2
First treatment for advanced colorectal cancer with combo chemo
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
BeijingAges 18–75 - NCT07389239RecruitingPhase 1/Phase 2
Immunotherapy for ovarian cancer and other advanced tumors
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT06840665RecruitingPhase 2
Radiation plus immunotherapy and chemo for rectal cancer
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07371234RecruitingPhase 2
Low-dose radiation and immunotherapy before surgery for head and neck cancer
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
GuangdongAges 18–75 - NCT07369882Recruiting
Less extensive surgery after immunotherapy for advanced head and neck cancer
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,550 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.